Patent US4749575A successfully refreshed from Google Patents.
US4749575A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Microencapsulated medicament in sweet matrix
Assignee: Bio Dar Ltd
•
Filing: 1986-01-29
•
Granted: 1988-06-07
•
Expires: 2006-01-29
Abstract
Abstract Any orally administrable medicament is prepared into a dosage form which eliminates the unpleasant taste and mouth feel of the medicament and is easily and pleasantly ingested even by children, by microencapsulating the medicament into microcapsules of less than 300 microns diameter, and embedding the microcapsules into a soft, sweet, palatable matrix, such as chocolate.
Inventors
- 👤 Avner Rotman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:10
CPC Classifications
A; A23; A23G; A23G1/00; A23G1/30; A23G1/32; A23G1/42; A23G1/426; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0056; A61K9/20; A61K9/2072; A61K9/2077; A61K9/2081
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
124 words
A sustained release unit dosage form for oral administration to human patients of a large dosage designed for gradual release of a pharmaceutically active principle which could cause a serious overdose if released immediately if not in sustained release form, comprising: a soft, sweet, palatable matrix which is sufficiently soft to allow mastication thereof without the necessity of substantial chewing, said matrix having substantially homogenously embedded therein macrocapsules of a large sustained release dosage of active principle, said microcapsules having a diameter below about 300 microns, and being present in said matrix in a quantity sufficient to provide a sustained release unit dose of said active principle in each bite-size unit of said matrix, said microcapsules being microencapsulated in gastric resistant sustained release material.
Claim 2
Dependent Claim
124 words
A sustained release unit dosage form for oral administration to human patients of a large dosage designed for gradual release of a pharmaceutically active principle which could cause a serious overdose if released immediately if not in sustained release form, comprising: a soft, sweet, palatable matrix which is sufficiently soft to allow mastication thereof without the necessity of substantial chewing, said matrix having substantially homogenously embedded therein macrocapsules of a large sustained release dosage of active principle, said microcapsules having a diameter below about 300 microns, and being present in said matrix in a quantity sufficient to provide a sustained release unit dose of said active principle in each bite-size unit of said matrix, said microcapsules being microencapsulated in gastric resistant sustained release material.
Claim 3
Dependent Claim
27 words
A dosage form in accordance with claim 1, wherein said matrix is selected from the group consisting of chocolate, fudge, marshmallow, peanut butter, carob or solid yogurt.
Claim 4
Dependent Claim
21 words
A dosage form in accordance with claim 1, wherein said matrix is one which has substantially the same consistency as chocolate.
Claim 5
Dependent Claim
17 words
A dosage form in accordance with claim 3, wherein said matrix is chocolate, carob or solid yoghurt.
Claim 6
Dependent Claim
13 words
A dosage form in accordance with claim 3, wherein said matrix is chocolate.
Claim 7
Dependent Claim
17 words
A dosage form in accordance with claim 5, wherein said matrix is sweet chocolate or milk chocolate.
Claim 8
Dependent Claim
32 words
A dosage form in accordance with claim 1, wherein said active principle is an anti-bacterial agent, analgesic, anti-histamine, decongestant, anti-inflammatory agent, anti-hypertensive agent, hypnotic, sedative, tranquilizer, alkaloid, diuretic, vasodilator, hormone or vitamin.
Claim 9
Dependent Claim
23 words
A dosage form in accordance with claim 1, wherein said microcapsules of active principle have a diameter of less than about 250 microns.
Claim 10
Dependent Claim
21 words
A dosage form in accordance with claim 1, wherein said microcapsules of active principle have a diameter of about 40-150 microns.
Claim 11
Dependent Claim
72 words
In the method of administering a unit dose of pharmaceutically active principle to a human patient in need of such active principle, comprising orally administering a unit dose of the active principle in a chewable administrative form, the improvement wherein said pharmaceutically active principle is in sustained release form in a large dosage designed for the gradual release thereof and comprises a sustained release unit dosage form in accordance with claim 1.
References Cited (Backward Citations)
FR717369A
Cited
US2538202A
Cited
US2634210A
Cited
FR68083E
Cited
US2957804A
Cited
GB875763A
Cited
US3520970A
Cited
US3697641A
Cited
GB1297221A
Cited
US3835221A
Cited
US3775537A
Cited
US3962416A
Cited
US3821422A
Cited
US3814819A
Cited
CH519858A
Cited
GB1342974A
Cited
US3860733A
Cited
GB1439240A
Cited
US4000322A
Cited
US3954959A
Cited
US3992555A
Cited
US3992556A
Cited
US4083949A
Cited
US4062986A
Cited
US4102806A
Cited
US4101651A
Cited
US4049832A
Cited
US4018900A
Cited
US4018901A
Cited
US4152462A
Cited
US4038423A
Cited
US4284652A
Cited
GB1598458A
Cited
US4153735A
Cited
US4191783A
Cited
US4182778A
Cited
US4230687A
Cited
US4271142A
Cited
GB2057847A
Cited
JPS56164102A
Cited
JPS5746901A
Cited
GB2092425A
Cited
FR2496403A1
Cited
US4490352A
Cited
US4327077A
Cited
JPS5813503A
Cited
US4587118A
Cited
US4543262A
Cited
BE900749A
Cited
FR2552665A1
Cited
DE3435747A1
Cited
NL8403003A
Cited
GB2147501A
Cited
JPS6094058A
Cited
JPS60102138A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-06-07 | 1991-12-07 | 1992-06-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-06-07 | 1995-12-07 | 1996-06-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-06-07 | 1999-12-07 | 2000-06-07 | $7700.00 | Window Closed / Lapsed |